tiprankstipranks
Trending News
More News >
Ascelia Pharma AB (SE:ACE)
:ACE
Advertisement

Ascelia Pharma AB (ACE) Price & Analysis

Compare
1 Followers

ACE Stock Chart & Stats


Financials

ACE FAQ

What was Ascelia Pharma AB’s price range in the past 12 months?
Ascelia Pharma AB lowest stock price was kr1.89 and its highest was kr5.00 in the past 12 months.
    What is Ascelia Pharma AB’s market cap?
    Ascelia Pharma AB’s market cap is kr489.63M.
      When is Ascelia Pharma AB’s upcoming earnings report date?
      Ascelia Pharma AB’s upcoming earnings report date is Aug 21, 2025 which is in 35 days.
        How were Ascelia Pharma AB’s earnings last quarter?
        Ascelia Pharma AB released its earnings results on May 16, 2025. The company reported -kr0.2 earnings per share for the quarter, the consensus estimate of -kr0.2 by kr0.
          Is Ascelia Pharma AB overvalued?
          According to Wall Street analysts Ascelia Pharma AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Ascelia Pharma AB pay dividends?
            Ascelia Pharma AB does not currently pay dividends.
            What is Ascelia Pharma AB’s EPS estimate?
            Ascelia Pharma AB’s EPS estimate is -0.1.
              How many shares outstanding does Ascelia Pharma AB have?
              Ascelia Pharma AB has 116,025,530 shares outstanding.
                What happened to Ascelia Pharma AB’s price movement after its last earnings report?
                Ascelia Pharma AB reported an EPS of -kr0.2 in its last earnings report, expectations of -kr0.2. Following the earnings report the stock price went down -2.097%.
                  Which hedge fund is a major shareholder of Ascelia Pharma AB?
                  Currently, no hedge funds are holding shares in SE:ACE

                  Company Description

                  Ascelia Pharma AB

                  Ascelia Pharma AB (ACE) is a Swedish specialty pharmaceutical company focused on the development of novel drugs that address unmet medical needs, primarily in the field of oncology. The company's lead product candidate, Orviglance (formerly known as Mangoral), is an oral imaging drug designed to enhance the visualization of liver metastases in patients with impaired kidney function undergoing MRI scans. Ascelia Pharma operates within the pharmaceutical sector, with a commitment to improving diagnostic procedures and treatment options for cancer patients.
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Immunicum AB
                  Isofol Medical AB
                  NextCell Pharma AB
                  Xbrane Biopharma AB
                  Xintela AB
                  Popular Stocks
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis